Delhi High Court interjects in Bristol-Myers/Natco patent dispute

1 August 2019

A patent dispute between USA-based pharma major Bristol-Myers Squibb (NYSE: BMY) and Indian pharma company Natco Pharma (BSE: 524816) has taken a new turn with the Delhi High Court awarding interim relief to Hyderabad-based Natco, setting aside an injunction filed by B-MS seeking to protect its anti-coagulant Eliquis (apixaban) against Natco’s copy product Apigat.

Natco launched its generic version in June. B-MS objected saying the product has a patent till September 2022. The drug was granted a patent in 2011.

While B-MS made prayers for a permanent injunction, restraining the Indian company from making, selling, distributing and marketing the drug, Natco contended that apixaban, used in the prevention and treatment of blood clots, had already been disclosed in an earlier patent filing by BMS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK